FDA approval for Zaynich marks a major milestone for India in developing innovative antibiotics
Zaynich targets multidrug-resistant bacteria, addressing one of the world's biggest public health threats
Zidebactam is only India's second FDA-approved new chemical entity, highlighting progress beyond generics
Wockhardt invested heavily in antibiotic research despite high costs, long timelines, and uncertain returns
As global drugmakers scale back antibiotic research, Indian firms have an opportunity to lead
Success in high-risk innovation can strengthen India's pharmaceutical industry and improve global health security